Search results
Showing 61 to 71 of 71 results for parkinson
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
First NICE-recommended treatment for Parkinson's set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
NICE’s new guideline is the first to offer comprehensive information on neurological conditions to help non-specialist healthcare professionals to identify people who should be referred for specialist assessment and care.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Five promising technologies that could help improve symptoms and quality of life for people with Parkinson’s disease have been conditionally recommended by NICE.